nodes	percent_of_prediction	percent_of_DWPC	metapath
Riluzole—ABCG2—Leflunomide—systemic scleroderma	0.2	0.369	CbGbCtD
Riluzole—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.124	0.228	CbGbCtD
Riluzole—CYP1A2—Pentoxifylline—systemic scleroderma	0.0865	0.159	CbGbCtD
Riluzole—CYP1A2—Leflunomide—systemic scleroderma	0.0825	0.152	CbGbCtD
Riluzole—ABCG2—Methotrexate—systemic scleroderma	0.0496	0.0914	CbGbCtD
Riluzole—SLC7A11—forelimb zeugopod—systemic scleroderma	0.038	0.693	CbGeAlD
Riluzole—SLC7A11—smooth muscle tissue—systemic scleroderma	0.00385	0.0703	CbGeAlD
Riluzole—SLC7A11—digestive system—systemic scleroderma	0.00304	0.0555	CbGeAlD
Riluzole—SLC7A11—lung—systemic scleroderma	0.00254	0.0463	CbGeAlD
Riluzole—SCN5A—digestive system—systemic scleroderma	0.00183	0.0334	CbGeAlD
Riluzole—SLC7A11—Betamethasone—Mometasone—systemic scleroderma	0.0017	0.323	CbGdCrCtD
Riluzole—SLC7A11—Dexamethasone—Mometasone—systemic scleroderma	0.0017	0.323	CbGdCrCtD
Riluzole—CYP1A1—skin of body—systemic scleroderma	0.00119	0.0217	CbGeAlD
Riluzole—CYP1A2—digestive system—systemic scleroderma	0.000962	0.0176	CbGeAlD
Riluzole—CYP1A1—digestive system—systemic scleroderma	0.000949	0.0173	CbGeAlD
Riluzole—SLC7A11—Dexamethasone—Prednisone—systemic scleroderma	0.000924	0.176	CbGdCrCtD
Riluzole—SLC7A11—Betamethasone—Prednisone—systemic scleroderma	0.000924	0.176	CbGdCrCtD
Riluzole—ABCG2—lung—systemic scleroderma	0.000835	0.0153	CbGeAlD
Riluzole—CYP1A2—lung—systemic scleroderma	0.000804	0.0147	CbGeAlD
Riluzole—CYP1A1—lung—systemic scleroderma	0.000793	0.0145	CbGeAlD
Riluzole—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000128	0.000321	CcSEcCtD
Riluzole—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000127	0.00032	CcSEcCtD
Riluzole—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000127	0.00032	CcSEcCtD
Riluzole—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000127	0.00032	CcSEcCtD
Riluzole—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000127	0.00032	CcSEcCtD
Riluzole—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000127	0.00032	CcSEcCtD
Riluzole—Myocardial infarction—Prednisone—systemic scleroderma	0.000127	0.00032	CcSEcCtD
Riluzole—Breast disorder—Methotrexate—systemic scleroderma	0.000127	0.00032	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000127	0.000319	CcSEcCtD
Riluzole—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000127	0.000319	CcSEcCtD
Riluzole—Hypersensitivity—Azathioprine—systemic scleroderma	0.000126	0.000318	CcSEcCtD
Riluzole—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000126	0.000318	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000126	0.000318	CcSEcCtD
Riluzole—Insomnia—Lisinopril—systemic scleroderma	0.000126	0.000317	CcSEcCtD
Riluzole—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000126	0.000316	CcSEcCtD
Riluzole—Paraesthesia—Lisinopril—systemic scleroderma	0.000125	0.000314	CcSEcCtD
Riluzole—Vomiting—Captopril—systemic scleroderma	0.000125	0.000314	CcSEcCtD
Riluzole—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000313	CcSEcCtD
Riluzole—Dyspnoea—Lisinopril—systemic scleroderma	0.000124	0.000312	CcSEcCtD
Riluzole—Rash—Captopril—systemic scleroderma	0.000124	0.000312	CcSEcCtD
Riluzole—Dermatitis—Captopril—systemic scleroderma	0.000124	0.000311	CcSEcCtD
Riluzole—Somnolence—Lisinopril—systemic scleroderma	0.000124	0.000311	CcSEcCtD
Riluzole—Headache—Captopril—systemic scleroderma	0.000123	0.00031	CcSEcCtD
Riluzole—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000123	0.000309	CcSEcCtD
Riluzole—Dyspepsia—Lisinopril—systemic scleroderma	0.000123	0.000308	CcSEcCtD
Riluzole—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000122	0.000307	CcSEcCtD
Riluzole—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000122	0.000307	CcSEcCtD
Riluzole—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000307	CcSEcCtD
Riluzole—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000307	CcSEcCtD
Riluzole—Asthma—Methotrexate—systemic scleroderma	0.000121	0.000306	CcSEcCtD
Riluzole—Infection—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000305	CcSEcCtD
Riluzole—Decreased appetite—Lisinopril—systemic scleroderma	0.000121	0.000304	CcSEcCtD
Riluzole—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00012	0.000302	CcSEcCtD
Riluzole—Fatigue—Lisinopril—systemic scleroderma	0.00012	0.000302	CcSEcCtD
Riluzole—Shock—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000302	CcSEcCtD
Riluzole—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000301	CcSEcCtD
Riluzole—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000119	0.0003	CcSEcCtD
Riluzole—Hypersensitivity—Leflunomide—systemic scleroderma	0.000119	0.0003	CcSEcCtD
Riluzole—Pancreatitis—Methotrexate—systemic scleroderma	0.000119	0.0003	CcSEcCtD
Riluzole—Constipation—Lisinopril—systemic scleroderma	0.000119	0.000299	CcSEcCtD
Riluzole—Pain—Lisinopril—systemic scleroderma	0.000119	0.000299	CcSEcCtD
Riluzole—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000119	0.000299	CcSEcCtD
Riluzole—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000298	CcSEcCtD
Riluzole—Bradycardia—Prednisone—systemic scleroderma	0.000118	0.000298	CcSEcCtD
Riluzole—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000297	CcSEcCtD
Riluzole—Diarrhoea—Azathioprine—systemic scleroderma	0.000117	0.000295	CcSEcCtD
Riluzole—Haemoglobin—Prednisone—systemic scleroderma	0.000117	0.000294	CcSEcCtD
Riluzole—Nausea—Captopril—systemic scleroderma	0.000117	0.000294	CcSEcCtD
Riluzole—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000116	0.000293	CcSEcCtD
Riluzole—Haemorrhage—Prednisone—systemic scleroderma	0.000116	0.000293	CcSEcCtD
Riluzole—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000292	CcSEcCtD
Riluzole—Asthenia—Leflunomide—systemic scleroderma	0.000116	0.000292	CcSEcCtD
Riluzole—Hallucination—Prednisone—systemic scleroderma	0.000116	0.000291	CcSEcCtD
Riluzole—Pancytopenia—Methotrexate—systemic scleroderma	0.000115	0.00029	CcSEcCtD
Riluzole—Feeling abnormal—Lisinopril—systemic scleroderma	0.000115	0.000289	CcSEcCtD
Riluzole—Pruritus—Leflunomide—systemic scleroderma	0.000115	0.000288	CcSEcCtD
Riluzole—Connective tissue disorder—Prednisone—systemic scleroderma	0.000114	0.000288	CcSEcCtD
Riluzole—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000287	CcSEcCtD
Riluzole—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000114	0.000286	CcSEcCtD
Riluzole—Neutropenia—Methotrexate—systemic scleroderma	0.000114	0.000286	CcSEcCtD
Riluzole—Dysuria—Methotrexate—systemic scleroderma	0.000114	0.000286	CcSEcCtD
Riluzole—Dizziness—Azathioprine—systemic scleroderma	0.000113	0.000285	CcSEcCtD
Riluzole—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000112	0.000281	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000111	0.000279	CcSEcCtD
Riluzole—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000111	0.000279	CcSEcCtD
Riluzole—Asthenia—Mycophenolic acid—systemic scleroderma	0.000111	0.000279	CcSEcCtD
Riluzole—Diarrhoea—Leflunomide—systemic scleroderma	0.000111	0.000279	CcSEcCtD
Riluzole—Urticaria—Lisinopril—systemic scleroderma	0.000111	0.000278	CcSEcCtD
Riluzole—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00011	0.000277	CcSEcCtD
Riluzole—Body temperature increased—Lisinopril—systemic scleroderma	0.00011	0.000277	CcSEcCtD
Riluzole—Abdominal pain—Lisinopril—systemic scleroderma	0.00011	0.000277	CcSEcCtD
Riluzole—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000275	CcSEcCtD
Riluzole—Pruritus—Mycophenolic acid—systemic scleroderma	0.000109	0.000275	CcSEcCtD
Riluzole—Vomiting—Azathioprine—systemic scleroderma	0.000109	0.000274	CcSEcCtD
Riluzole—Pneumonia—Methotrexate—systemic scleroderma	0.000109	0.000274	CcSEcCtD
Riluzole—Eye disorder—Prednisone—systemic scleroderma	0.000109	0.000274	CcSEcCtD
Riluzole—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000273	CcSEcCtD
Riluzole—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000273	CcSEcCtD
Riluzole—Infestation NOS—Methotrexate—systemic scleroderma	0.000108	0.000272	CcSEcCtD
Riluzole—Infestation—Methotrexate—systemic scleroderma	0.000108	0.000272	CcSEcCtD
Riluzole—Rash—Azathioprine—systemic scleroderma	0.000108	0.000272	CcSEcCtD
Riluzole—Dermatitis—Azathioprine—systemic scleroderma	0.000108	0.000272	CcSEcCtD
Riluzole—Depression—Methotrexate—systemic scleroderma	0.000108	0.000272	CcSEcCtD
Riluzole—Headache—Azathioprine—systemic scleroderma	0.000107	0.00027	CcSEcCtD
Riluzole—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000107	0.00027	CcSEcCtD
Riluzole—Dizziness—Leflunomide—systemic scleroderma	0.000107	0.000269	CcSEcCtD
Riluzole—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000267	CcSEcCtD
Riluzole—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000106	0.000266	CcSEcCtD
Riluzole—Stomatitis—Methotrexate—systemic scleroderma	0.000106	0.000266	CcSEcCtD
Riluzole—Angiopathy—Prednisone—systemic scleroderma	0.000106	0.000266	CcSEcCtD
Riluzole—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000265	CcSEcCtD
Riluzole—Immune system disorder—Prednisone—systemic scleroderma	0.000105	0.000264	CcSEcCtD
Riluzole—Pain—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000262	CcSEcCtD
Riluzole—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000262	CcSEcCtD
Riluzole—Arrhythmia—Prednisone—systemic scleroderma	0.000104	0.000261	CcSEcCtD
Riluzole—Sweating—Methotrexate—systemic scleroderma	0.000104	0.000261	CcSEcCtD
Riluzole—Haematuria—Methotrexate—systemic scleroderma	0.000103	0.00026	CcSEcCtD
Riluzole—Vomiting—Leflunomide—systemic scleroderma	0.000103	0.000259	CcSEcCtD
Riluzole—Alopecia—Prednisone—systemic scleroderma	0.000103	0.000259	CcSEcCtD
Riluzole—Hypersensitivity—Lisinopril—systemic scleroderma	0.000103	0.000258	CcSEcCtD
Riluzole—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000102	0.000258	CcSEcCtD
Riluzole—Dizziness—Mycophenolic acid—systemic scleroderma	0.000102	0.000257	CcSEcCtD
Riluzole—Epistaxis—Methotrexate—systemic scleroderma	0.000102	0.000257	CcSEcCtD
Riluzole—Rash—Leflunomide—systemic scleroderma	0.000102	0.000257	CcSEcCtD
Riluzole—Dermatitis—Leflunomide—systemic scleroderma	0.000102	0.000257	CcSEcCtD
Riluzole—Mental disorder—Prednisone—systemic scleroderma	0.000102	0.000256	CcSEcCtD
Riluzole—Nausea—Azathioprine—systemic scleroderma	0.000102	0.000256	CcSEcCtD
Riluzole—Headache—Leflunomide—systemic scleroderma	0.000101	0.000255	CcSEcCtD
Riluzole—Malnutrition—Prednisone—systemic scleroderma	0.000101	0.000255	CcSEcCtD
Riluzole—Agranulocytosis—Methotrexate—systemic scleroderma	0.000101	0.000254	CcSEcCtD
Riluzole—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.0001	0.000253	CcSEcCtD
Riluzole—Asthenia—Lisinopril—systemic scleroderma	9.99e-05	0.000251	CcSEcCtD
Riluzole—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	9.97e-05	0.000251	CcSEcCtD
Riluzole—Pruritus—Lisinopril—systemic scleroderma	9.85e-05	0.000248	CcSEcCtD
Riluzole—Vomiting—Mycophenolic acid—systemic scleroderma	9.82e-05	0.000247	CcSEcCtD
Riluzole—Haemoglobin—Methotrexate—systemic scleroderma	9.77e-05	0.000246	CcSEcCtD
Riluzole—Rash—Mycophenolic acid—systemic scleroderma	9.74e-05	0.000245	CcSEcCtD
Riluzole—Dermatitis—Mycophenolic acid—systemic scleroderma	9.73e-05	0.000245	CcSEcCtD
Riluzole—Hepatitis—Methotrexate—systemic scleroderma	9.72e-05	0.000245	CcSEcCtD
Riluzole—Haemorrhage—Methotrexate—systemic scleroderma	9.72e-05	0.000245	CcSEcCtD
Riluzole—Urticaria—Mycophenolate mofetil—systemic scleroderma	9.69e-05	0.000244	CcSEcCtD
Riluzole—Headache—Mycophenolic acid—systemic scleroderma	9.68e-05	0.000244	CcSEcCtD
Riluzole—Pharyngitis—Methotrexate—systemic scleroderma	9.65e-05	0.000243	CcSEcCtD
Riluzole—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	9.64e-05	0.000243	CcSEcCtD
Riluzole—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	9.64e-05	0.000243	CcSEcCtD
Riluzole—Nausea—Leflunomide—systemic scleroderma	9.62e-05	0.000242	CcSEcCtD
Riluzole—Urinary tract disorder—Methotrexate—systemic scleroderma	9.6e-05	0.000242	CcSEcCtD
Riluzole—Urethral disorder—Methotrexate—systemic scleroderma	9.53e-05	0.00024	CcSEcCtD
Riluzole—Diarrhoea—Lisinopril—systemic scleroderma	9.52e-05	0.00024	CcSEcCtD
Riluzole—Ill-defined disorder—Prednisone—systemic scleroderma	9.4e-05	0.000236	CcSEcCtD
Riluzole—Anaemia—Prednisone—systemic scleroderma	9.36e-05	0.000235	CcSEcCtD
Riluzole—Agitation—Prednisone—systemic scleroderma	9.31e-05	0.000234	CcSEcCtD
Riluzole—Angioedema—Prednisone—systemic scleroderma	9.25e-05	0.000233	CcSEcCtD
Riluzole—Dizziness—Lisinopril—systemic scleroderma	9.2e-05	0.000232	CcSEcCtD
Riluzole—Erythema multiforme—Methotrexate—systemic scleroderma	9.19e-05	0.000231	CcSEcCtD
Riluzole—Nausea—Mycophenolic acid—systemic scleroderma	9.18e-05	0.000231	CcSEcCtD
Riluzole—Malaise—Prednisone—systemic scleroderma	9.13e-05	0.00023	CcSEcCtD
Riluzole—Vertigo—Prednisone—systemic scleroderma	9.1e-05	0.000229	CcSEcCtD
Riluzole—Eye disorder—Methotrexate—systemic scleroderma	9.09e-05	0.000229	CcSEcCtD
Riluzole—Syncope—Prednisone—systemic scleroderma	9.08e-05	0.000228	CcSEcCtD
Riluzole—Cardiac disorder—Methotrexate—systemic scleroderma	9.02e-05	0.000227	CcSEcCtD
Riluzole—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	8.98e-05	0.000226	CcSEcCtD
Riluzole—Loss of consciousness—Prednisone—systemic scleroderma	8.9e-05	0.000224	CcSEcCtD
Riluzole—Vomiting—Lisinopril—systemic scleroderma	8.85e-05	0.000223	CcSEcCtD
Riluzole—Angiopathy—Methotrexate—systemic scleroderma	8.82e-05	0.000222	CcSEcCtD
Riluzole—Immune system disorder—Methotrexate—systemic scleroderma	8.78e-05	0.000221	CcSEcCtD
Riluzole—Rash—Lisinopril—systemic scleroderma	8.78e-05	0.000221	CcSEcCtD
Riluzole—Convulsion—Prednisone—systemic scleroderma	8.78e-05	0.000221	CcSEcCtD
Riluzole—Dermatitis—Lisinopril—systemic scleroderma	8.77e-05	0.000221	CcSEcCtD
Riluzole—Mediastinal disorder—Methotrexate—systemic scleroderma	8.76e-05	0.00022	CcSEcCtD
Riluzole—Asthenia—Mycophenolate mofetil—systemic scleroderma	8.75e-05	0.00022	CcSEcCtD
Riluzole—Hypertension—Prednisone—systemic scleroderma	8.74e-05	0.00022	CcSEcCtD
Riluzole—Chills—Methotrexate—systemic scleroderma	8.72e-05	0.000219	CcSEcCtD
Riluzole—Headache—Lisinopril—systemic scleroderma	8.72e-05	0.000219	CcSEcCtD
Riluzole—Pruritus—Mycophenolate mofetil—systemic scleroderma	8.63e-05	0.000217	CcSEcCtD
Riluzole—Myalgia—Prednisone—systemic scleroderma	8.62e-05	0.000217	CcSEcCtD
Riluzole—Arthralgia—Prednisone—systemic scleroderma	8.62e-05	0.000217	CcSEcCtD
Riluzole—Anxiety—Prednisone—systemic scleroderma	8.59e-05	0.000216	CcSEcCtD
Riluzole—Alopecia—Methotrexate—systemic scleroderma	8.59e-05	0.000216	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	8.56e-05	0.000215	CcSEcCtD
Riluzole—Discomfort—Prednisone—systemic scleroderma	8.52e-05	0.000214	CcSEcCtD
Riluzole—Mental disorder—Methotrexate—systemic scleroderma	8.52e-05	0.000214	CcSEcCtD
Riluzole—Malnutrition—Methotrexate—systemic scleroderma	8.46e-05	0.000213	CcSEcCtD
Riluzole—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	8.34e-05	0.00021	CcSEcCtD
Riluzole—Dysgeusia—Methotrexate—systemic scleroderma	8.29e-05	0.000209	CcSEcCtD
Riluzole—Nausea—Lisinopril—systemic scleroderma	8.27e-05	0.000208	CcSEcCtD
Riluzole—Anaphylactic shock—Prednisone—systemic scleroderma	8.27e-05	0.000208	CcSEcCtD
Riluzole—Oedema—Prednisone—systemic scleroderma	8.27e-05	0.000208	CcSEcCtD
Riluzole—Infection—Prednisone—systemic scleroderma	8.21e-05	0.000207	CcSEcCtD
Riluzole—Back pain—Methotrexate—systemic scleroderma	8.19e-05	0.000206	CcSEcCtD
Riluzole—Shock—Prednisone—systemic scleroderma	8.13e-05	0.000205	CcSEcCtD
Riluzole—Nervous system disorder—Prednisone—systemic scleroderma	8.11e-05	0.000204	CcSEcCtD
Riluzole—Tachycardia—Prednisone—systemic scleroderma	8.07e-05	0.000203	CcSEcCtD
Riluzole—Dizziness—Mycophenolate mofetil—systemic scleroderma	8.06e-05	0.000203	CcSEcCtD
Riluzole—Skin disorder—Prednisone—systemic scleroderma	8.03e-05	0.000202	CcSEcCtD
Riluzole—Hyperhidrosis—Prednisone—systemic scleroderma	7.99e-05	0.000201	CcSEcCtD
Riluzole—Anorexia—Prednisone—systemic scleroderma	7.88e-05	0.000198	CcSEcCtD
Riluzole—Ill-defined disorder—Methotrexate—systemic scleroderma	7.85e-05	0.000198	CcSEcCtD
Riluzole—Anaemia—Methotrexate—systemic scleroderma	7.82e-05	0.000197	CcSEcCtD
Riluzole—Vomiting—Mycophenolate mofetil—systemic scleroderma	7.75e-05	0.000195	CcSEcCtD
Riluzole—Rash—Mycophenolate mofetil—systemic scleroderma	7.69e-05	0.000193	CcSEcCtD
Riluzole—Dermatitis—Mycophenolate mofetil—systemic scleroderma	7.68e-05	0.000193	CcSEcCtD
Riluzole—Headache—Mycophenolate mofetil—systemic scleroderma	7.64e-05	0.000192	CcSEcCtD
Riluzole—Malaise—Methotrexate—systemic scleroderma	7.63e-05	0.000192	CcSEcCtD
Riluzole—Vertigo—Methotrexate—systemic scleroderma	7.6e-05	0.000191	CcSEcCtD
Riluzole—Leukopenia—Methotrexate—systemic scleroderma	7.58e-05	0.000191	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Prednisone—systemic scleroderma	7.53e-05	0.000189	CcSEcCtD
Riluzole—Insomnia—Prednisone—systemic scleroderma	7.48e-05	0.000188	CcSEcCtD
Riluzole—Paraesthesia—Prednisone—systemic scleroderma	7.42e-05	0.000187	CcSEcCtD
Riluzole—Cough—Methotrexate—systemic scleroderma	7.39e-05	0.000186	CcSEcCtD
Riluzole—Convulsion—Methotrexate—systemic scleroderma	7.33e-05	0.000184	CcSEcCtD
Riluzole—Dyspepsia—Prednisone—systemic scleroderma	7.28e-05	0.000183	CcSEcCtD
Riluzole—Nausea—Mycophenolate mofetil—systemic scleroderma	7.24e-05	0.000182	CcSEcCtD
Riluzole—Chest pain—Methotrexate—systemic scleroderma	7.21e-05	0.000181	CcSEcCtD
Riluzole—Arthralgia—Methotrexate—systemic scleroderma	7.21e-05	0.000181	CcSEcCtD
Riluzole—Myalgia—Methotrexate—systemic scleroderma	7.21e-05	0.000181	CcSEcCtD
Riluzole—Decreased appetite—Prednisone—systemic scleroderma	7.19e-05	0.000181	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	7.16e-05	0.00018	CcSEcCtD
Riluzole—Fatigue—Prednisone—systemic scleroderma	7.13e-05	0.000179	CcSEcCtD
Riluzole—Discomfort—Methotrexate—systemic scleroderma	7.12e-05	0.000179	CcSEcCtD
Riluzole—Constipation—Prednisone—systemic scleroderma	7.07e-05	0.000178	CcSEcCtD
Riluzole—Confusional state—Methotrexate—systemic scleroderma	6.97e-05	0.000175	CcSEcCtD
Riluzole—Anaphylactic shock—Methotrexate—systemic scleroderma	6.91e-05	0.000174	CcSEcCtD
Riluzole—Infection—Methotrexate—systemic scleroderma	6.86e-05	0.000173	CcSEcCtD
Riluzole—Feeling abnormal—Prednisone—systemic scleroderma	6.81e-05	0.000171	CcSEcCtD
Riluzole—Nervous system disorder—Methotrexate—systemic scleroderma	6.77e-05	0.00017	CcSEcCtD
Riluzole—Thrombocytopenia—Methotrexate—systemic scleroderma	6.76e-05	0.00017	CcSEcCtD
Riluzole—Gastrointestinal pain—Prednisone—systemic scleroderma	6.76e-05	0.00017	CcSEcCtD
Riluzole—Skin disorder—Methotrexate—systemic scleroderma	6.71e-05	0.000169	CcSEcCtD
Riluzole—Hyperhidrosis—Methotrexate—systemic scleroderma	6.68e-05	0.000168	CcSEcCtD
Riluzole—Anorexia—Methotrexate—systemic scleroderma	6.58e-05	0.000166	CcSEcCtD
Riluzole—Urticaria—Prednisone—systemic scleroderma	6.57e-05	0.000165	CcSEcCtD
Riluzole—Abdominal pain—Prednisone—systemic scleroderma	6.53e-05	0.000164	CcSEcCtD
Riluzole—Body temperature increased—Prednisone—systemic scleroderma	6.53e-05	0.000164	CcSEcCtD
Riluzole—Hypotension—Methotrexate—systemic scleroderma	6.46e-05	0.000162	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	6.29e-05	0.000158	CcSEcCtD
Riluzole—Insomnia—Methotrexate—systemic scleroderma	6.25e-05	0.000157	CcSEcCtD
Riluzole—Paraesthesia—Methotrexate—systemic scleroderma	6.2e-05	0.000156	CcSEcCtD
Riluzole—Dyspnoea—Methotrexate—systemic scleroderma	6.16e-05	0.000155	CcSEcCtD
Riluzole—Somnolence—Methotrexate—systemic scleroderma	6.14e-05	0.000154	CcSEcCtD
Riluzole—Hypersensitivity—Prednisone—systemic scleroderma	6.09e-05	0.000153	CcSEcCtD
Riluzole—Dyspepsia—Methotrexate—systemic scleroderma	6.08e-05	0.000153	CcSEcCtD
Riluzole—Decreased appetite—Methotrexate—systemic scleroderma	6.01e-05	0.000151	CcSEcCtD
Riluzole—Gastrointestinal disorder—Methotrexate—systemic scleroderma	5.96e-05	0.00015	CcSEcCtD
Riluzole—Fatigue—Methotrexate—systemic scleroderma	5.96e-05	0.00015	CcSEcCtD
Riluzole—Asthenia—Prednisone—systemic scleroderma	5.93e-05	0.000149	CcSEcCtD
Riluzole—Pain—Methotrexate—systemic scleroderma	5.91e-05	0.000149	CcSEcCtD
Riluzole—Pruritus—Prednisone—systemic scleroderma	5.85e-05	0.000147	CcSEcCtD
Riluzole—Feeling abnormal—Methotrexate—systemic scleroderma	5.69e-05	0.000143	CcSEcCtD
Riluzole—Diarrhoea—Prednisone—systemic scleroderma	5.66e-05	0.000142	CcSEcCtD
Riluzole—Gastrointestinal pain—Methotrexate—systemic scleroderma	5.65e-05	0.000142	CcSEcCtD
Riluzole—Urticaria—Methotrexate—systemic scleroderma	5.49e-05	0.000138	CcSEcCtD
Riluzole—Dizziness—Prednisone—systemic scleroderma	5.47e-05	0.000138	CcSEcCtD
Riluzole—Abdominal pain—Methotrexate—systemic scleroderma	5.46e-05	0.000137	CcSEcCtD
Riluzole—Body temperature increased—Methotrexate—systemic scleroderma	5.46e-05	0.000137	CcSEcCtD
Riluzole—Vomiting—Prednisone—systemic scleroderma	5.26e-05	0.000132	CcSEcCtD
Riluzole—Rash—Prednisone—systemic scleroderma	5.21e-05	0.000131	CcSEcCtD
Riluzole—Dermatitis—Prednisone—systemic scleroderma	5.21e-05	0.000131	CcSEcCtD
Riluzole—Headache—Prednisone—systemic scleroderma	5.18e-05	0.00013	CcSEcCtD
Riluzole—Hypersensitivity—Methotrexate—systemic scleroderma	5.09e-05	0.000128	CcSEcCtD
Riluzole—Asthenia—Methotrexate—systemic scleroderma	4.96e-05	0.000125	CcSEcCtD
Riluzole—Nausea—Prednisone—systemic scleroderma	4.91e-05	0.000124	CcSEcCtD
Riluzole—Pruritus—Methotrexate—systemic scleroderma	4.89e-05	0.000123	CcSEcCtD
Riluzole—Diarrhoea—Methotrexate—systemic scleroderma	4.73e-05	0.000119	CcSEcCtD
Riluzole—Dizziness—Methotrexate—systemic scleroderma	4.57e-05	0.000115	CcSEcCtD
Riluzole—Vomiting—Methotrexate—systemic scleroderma	4.39e-05	0.00011	CcSEcCtD
Riluzole—Rash—Methotrexate—systemic scleroderma	4.36e-05	0.00011	CcSEcCtD
Riluzole—Dermatitis—Methotrexate—systemic scleroderma	4.35e-05	0.000109	CcSEcCtD
Riluzole—Headache—Methotrexate—systemic scleroderma	4.33e-05	0.000109	CcSEcCtD
Riluzole—Nausea—Methotrexate—systemic scleroderma	4.1e-05	0.000103	CcSEcCtD
